Compare Cassava Sciences Inc (FLNA) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Solaredge Technologies Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Solaredge Technologies Inc trades at $54.62 (market cap $3.32B). The key difference: Solaredge Technologies Inc is far larger — about 62.5× Cassava Sciences Inc's market cap, and Solaredge Technologies Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SEDG | |
|---|---|---|
Market Cap | $53.14M | $3.32B |
Sector | Health | Technology |
52-Week High | $4.64 | $78.51 |
52-Week Low | $1.09 | $24.42 |
Enterprise Value | -$33.43M | $3.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
SolarEdge Technologies (SEDG) trades at $52.00, down 6.34% in the past 24 hours, with technical indicators showing a neutral signal. The company reported a net loss of $405.45 million in 2025 despite revenue of $1.18 billion, with negative profit margins and ROE. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Analyst sentiment is divided, with a consensus price target of $35.65, below the current price. Cash flow improved in 2025, but high debt levels and competitive pressures remain concerns.
The outlook for SEDG is cautious due to persistent losses and weak profitability, though recent cash flow improvement offers some stability. Investment opportunities hinge on solar demand recovery and execution on cost controls. Key risks include intense competition, regulatory uncertainty, and reliance on solar market cycles. Investors should monitor upcoming Q2 2026 earnings for signs of turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
